SG Americas Securities
AMRI

SG Americas Securities’s Albany Molecular Research Inc AMRI Stock Holding History

SG Americas Securities’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-47,443
Closed -$1.03M – 3892
2017
Q2 		$1.03M Buy
47,443
+37,440
+374% +$680K 0.01% 1387
2017
Q1 		$140K Sell
10,003
-6,235
-38% -$102K ﹤0.01% 2719
2016
Q4 		$305K Buy
+16,238
New +$276K ﹤0.01% 2019
2015
Q1 		– Sell
-9,593
Closed -$156K – 3311
2014
Q4 		$156K Buy
+9,593
New +$176K ﹤0.01% 2621

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

SG Americas Securities's AMRI Position: Q3 2017 in Review

SG Americas Securities sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 47,443 shares — an estimated $1.03M sold.

SG Americas Securities first reported a position in AMRI in Q4 2014 and held it in 4 quarters. The position peaked at $1.03M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • SG Americas Securities reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • SG Americas Securities sold 47,443 Albany Molecular Research Inc shares in Q3 2017, an estimated $1.03M.
  • SG Americas Securities first reported a position in Albany Molecular Research Inc in Q4 2014 and held it in 4 quarters.
  • SG Americas Securities's Albany Molecular Research Inc position peaked at $1.03M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on SG Americas Securities's 13F filing for Q3 2017, filed 7 Nov 2017.